{
  "abstract": "Background and Importance Carboplatin is widely used in standard chemotherapy regimens. Its dosage is calculated using the Calvert formula, which incorporates the area under the curve (AUC) and glomerular filtration rate, estimated using creatinine clearance (Cr) via the Cockcroft-Gault equation. As overweight patients were underrepresented in its validation, several scientific societies recommend using adjusted ideal weight (AIW) in these patients to avoid carboplatin overdose and associated toxicity.Aim and Objectives Retrospectively analyse carboplatin dosing in cancer patients to determine whether overweight patients were overdosed by comparing actual weight prescribed dose ( ARdose) and AIW calculated dose (AIWdose). In addition, study the possible relationship between overdose and toxicity onset.Material and Methods All patients receiving paclitaxel-carboplatin every 21 days, whose first cycle of chemotherapy occurred between 01/06/2024-31/03/2025, were studied.Data collected from Farmis-oncofarm and Orion clinic included:sex, age, weight, height, body mass index (BMI), ARdose in cycle 1, Cr, AUC and percentage of prescribed dose. Patients were classified as BMI<25 or BMI≥25 (overweight). The AIWdose was calculated using AIW and the same values for the variables mentioned. Variation between ARdose and AIWdose in overweight patients was calculated as: [(ARdose-AIWdose)/AIWdose]x100; positive value indicates overdose.Dose reductions and their causes were recorded. If dose reduction was due to toxicity and overweight, the relationship with overdose was studied.Results Thirty-eight patients were included, with a median of 65(18) years, 24(63.2%) of whom were women. The mean weight and height were 73.5(12.6)kg and 161.3(7.9)cm, respectively. Twenty-nine(76.3%) patients were overweight (BMI≥25). The mean ARdose in the first cycle was 564.7(116.7)mg, with Cr 0.8(0.2)mg/dL; AUC used was: 4(5.3%), 5(84.2%), 6(10.5%).For overweight patients, the mean ARdose was 567.0(123.8)mg, the mean AIWdose 501.8(118.4)mg, and the mean variation 13.7(8.8)%.In 16/38(42.1%) patients there was a dose reduction: 1/16(6.3%) due to worsening Cr, 6/16(37.5%) due to weight change, 7/16(43.8%) due to toxicity, and 2/16(12.5%) due to the latter two factors.Of the 9/38 patients with toxicity, 7/9(77.8%) were patients with a BMI≥25.Conclusion and Relevance In the population studied, the difference between ARdose and AIWdose indicates overdose in overweight patients. Most carboplatin-related toxicity cases occurred in these patients. These findings suggest that using AIW for dosing may reduce toxicity risk and warrant prospective confirmation.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "I Castejon Grao"
    },
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "V García Zafra"
    },
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "I Carreño Dato"
    },
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "I Jiménez Pulido"
    },
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "C Matoses Chirivella"
    },
    {
      "affiliations": [
        "Hospital General Universitario De Elche, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "AC Murcia Lopez"
    }
  ],
  "title": "5PSQ-122 Impact of using adjusted ideal weight for carboplatin dosing in overweight oncology patients: a retrospective analysis",
  "uid": "60ef4364-2299-5e10-9725-3064b50dbd74"
}